{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.1","upperLimit":"99.9","value":"95.0"},{"groupId":"OG001","lowerLimit":"74.2","upperLimit":"98.0","value":"90.3"},{"groupId":"OG002","lowerLimit":"66.9","upperLimit":"98.7","value":"89.5"},{"groupId":"OG003","lowerLimit":"47.8","upperLimit":"100","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"The DCR was defined as the percentage of patients who achieved a best overall response (BOR) of complete response (CR), partial response (PR) or stable disease (SD) as determined by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with NET of lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG000","title":"Cohort A (NET, Lung)"},{"description":"Patients with NET of small bowel origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG001","title":"Cohort B (NET, Small Bowel)"},{"description":"Patients with NET of non-small bowel, non-pancreas, and non-lung origin received surufatinib 300 mg orally QD in treatment cycles of 28 days starting on C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG002","title":"Cohort C (NET, Other)"},{"description":"Patients with NET of any origin received a single dose of drug cocktail (midazolam 2.5 mg, fexofenadine 30 mg and rosuvastatin 10 mg) on Day -2 followed by surufatinib 300 mg orally QD from C1D1 to C1D14. On C1D15, a single dose of surufatinib 300 mg and a single dose of drug cocktail as above was administered. Patients received surufatinib 300 mg orally QD from C1D16 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG003","title":"Cohort D (NET, Any)"}],"paramType":"NUMBER","populationDescription":"The efficacy analysis set included all patients who received at least 1 dose of surufatinib and had at least 1 post-baseline tumor assessment.","reportingStatus":"POSTED","timeFrame":"RECIST assessments performed at screening (within 28 days before start of study drug), every 8 weeks for the first 24 weeks from C1D1, then every 12 weeks thereafter until the occurrence of disease progression, up to approximately 36 months","title":"Disease Control Rate (DCR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}